Page 2 - சேதி லெவிஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Supercomputer at SSCC: 320 mini computers make mega mainframe
wnewsj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wnewsj.com Daily Mail and Mail on Sunday newspapers.
Supercomputer at SSCC: 320 mini computers make mega mainframe
timesgazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesgazette.com Daily Mail and Mail on Sunday newspapers.
Peter Sommer Quartet: In the Shadow of the Colossus
kuvo.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuvo.org Daily Mail and Mail on Sunday newspapers.
Peter Sommer has contributed his energetic tenor playing and creative spirit to a wide variety of musical projects ranging from mainstream bebop to avant garde and beyond at venues across the nation and around the world. Although rooted in the great jazz tradition of his heroes Duke Ellington, Thelonious Monk, John Coltrane and Ornette Coleman, he continues to search for the mystery in music making and takes great joy in sharing the present moment with the listener. Peter Sommer is Associate Professor of Jazz Studies and Saxophone at Colorado State University in Ft. Collins. At CSU, Mr. Sommer directs Jazz Ensemble I and coordinates the Jazz Studies area. Peter is a D’Addario endorsed Woodwinds Artist.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in .
Molecular PartnersJuly 8, 2021 GMT
Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern
EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with interim data expected in H2 2021 and full topline data expected in early 2022
ACTIV-3, a Phase 3 trial enrolling hospitalized patients across 4 countries with more countries expected to be added in the coming months, with topline data expected in 2022